Will Government further expand reimbursement for rare leukaemia drugs?

Korea Biomedical Review

17 August 2021 - As the Government has gradually increased reimbursement for combination drugs treating chronic lymphocytic leukaemia, patients’ hopes are growing for more diverse treatment options.

Recently, access to its treatment options using oral drugs alone or in combination with others has been enhanced in Korea, considering the characteristics of the disease with a high proportion of elderly patients.

Read Korea Biomedical Review article

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Cancer , Medicine , Market access , Korea